Dr. Robert Langer, Pioneer in Drug Delivery Systems and Regenerative Medicine Joins CHS Pharma, Inc. as a Member of its Board of

  Dr. Robert Langer, Pioneer in Drug Delivery Systems and Regenerative
  Medicine Joins CHS Pharma, Inc. as a Member of its Board of Directors and
  Scientific Advisory Board

Business Wire

JUPITER, Fla. -- June 26, 2013

CHS Pharma Inc., an emerging biotechnology company located in Jupiter,
Florida, has announced the addition of Robert S. Langer, Sc.D., to its Board
of Directors and Scientific Advisory Board. Langer has made pioneering
contributions in drug delivery and regenerative medicine, and together with
Judah Folkman, M.D., the founder of the field of angiogenesis, isolated the
first substances that stopped blood vessels from growing which led to the
first treatment for wet age-related macular degeneration (AMD) and many forms
of cancer. Langer is one of 13 institute professors at the Massachusetts
Institute of Technology (MIT’s highest honor) and holds more than 800 issued
and pending patents. He is the most cited engineer in history with more than
90,000 citations and is the only person to be elected to all four U.S.
national academies — Science, Engineering, Inventors, and Medicine, as well as
having received the national medal of science and the national medal of
technology and innovation.

“Dr. Langer’s expertise, coupled with our existing team will enable CHS to
develop cutting-edge drugs that will have a major impact on multiple medical
conditions,” said Stephen Chakoff, President & CEO of CHS Pharma Inc.

CHS’s platform technology includes treatments for cancer using a unique
mechanism that protects normal cells while destroying cancer cells, as well as
a treatment for AMD caused by oxidative damage, such as a treatment for
individuals who are losing their sight due to dry AMD.

“Dry macular degeneration affects more than 30 million people and currently
there are no highly effective treatment options available,” said Houman David
Hemmati, M.D., Ph.D., an ophthalmologist. “CHS’s technology holds significant
promise to resolve this unmet need.”

Langer previously served as the chair of the U.S. Food and Drug
Administration’s (FDA) Science Board (their highest advisory board) and on the
board of directors for Alkermes, Wyeth, and Millipore. He has received more
than 200 awards including the Draper prize, which is considered the
engineering Nobel Prize, the Wolf prize in chemistry, the Albany Medical Prize
(the largest medical prize in the U.S.), and he holds 20 honorary doctorates
including ones from Harvard and Yale.

“I’m delighted to be working with the CHS team on creating new therapeutics
for dry AMD and other diseases,” said Langer.

CHS Pharma (www.chspharma.com) owns a platform technology, backed by an
intellectual property portfolio consisting of four issued patents, two
recently allowed and nine pending patent applications in the U.S. and abroad.
CHS’s patented platform technology covers other potential treatments for
illnesses such as stroke and cardiovascular disease. This technology is based
on the discoveries by former pharmaceutical executive Herbert Weissbach,
Ph.D., the current director of the Center for Molecular Biology and
Biotechnology in Jupiter, Florida, and his collaborators at the Hospital for
Special Surgery, affiliated with the Weill Cornell Medical College in New
York. Weissbach helped found the Roche Institute for Molecular Biology and
Biotechnology and served as a Vice-President of Research at Roche. He is a
member of both the National Academy of Science and the National Academy of

“CHS Pharma is fortunate to have Dr. Langer who is a distinguished scientist
and engineer on its Board of Directors,” said Weissbach. “His experience and
success in helping life science companies develop their technologies will be
of immense value to the company.”


CHS Pharma Inc.
Saeid Rezvankhah, 561-748-9393
Chief Operating Officer
Press spacebar to pause and continue. Press esc to stop.